Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock.
San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio.
Cytori will acquire a pair of experimental cancer drugs, ATI-0918 and ATI-1123, which were designed to deliver chemotherapies more effectively and with fewer side effects than traditional formulations.
Get the full story at our sister site, Drug Delivery Business News.